18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer
18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer
复制标题
DOI：
10.21873/anticanres.16141
复制
发表时间：
2023-01-01
影响因子：
2
通讯作者：
Okada, Morihito
中科院分区：
文献类型：
--
作者：
Kimura, Yuri;Sasada, Shinsuke;Okada, Morihito
背景/目的：使用18 F-氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）获得的最大标准化摄取值（SUVmax）被假定为基于其糖酵解活性指示肿瘤免疫微环境（TIME）中的肿瘤和活性免疫细胞。因此，本研究调查了代谢参数SUVmax是否可以提供关于三阴性乳腺癌（TNBC）患者的TIME的信息。患者和方法：54例TNBC患者在新辅助化疗前接受FDG PET/CT检查。对治疗前活检标本进行病理学评价。免疫组化检测CD 8、FOXP 3、PD-1、PD-L1的表达。观察肿瘤浸润淋巴细胞（TIL）分级与SUVmax或病理完全反应（pCR）的关系。结果：CD 8、FOXP 3、PD-1和PD-L1分别在15例（27.8%）、39例（72.2%）、18例（33.3%）和26例（48.2%）患者中升高。SUVmax与肿瘤大小、Ki-67标记指数和CD 8/FOXP 3比值显著相关。多元线性回归分析表明肿瘤大小和CD 8/FOXP 3比值预测SUVmax。17例患者（31.5%）达到pCR; TIL、CD 8/FOXP 3比值、PD-1和PD-L1与pCR率显著相关。多因素分析显示CD 8/FOXP 3比值是pCR的唯一独立预测因素。结论：SUVmax可以提供TNBC患者关于TIME的代谢信息，可能有助于制定治疗策略和预测新辅助化疗后的pCR。
Background/Aim: The maximum standardized uptake value (SUVmax) obtained using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is presumed to indicate tumor and active immune cells in the tumor immune microenvironment (TIME) based on their glycolysis activity. Therefore, this study investigated whether the metabolic parameter SUVmax could provide information regarding TIME in triple-negative breast cancer (TNBC) patients. Patients and Methods: Fifty-four patients with TNBC underwent FDG PET/CT before neoadjuvant chemotherapy. Pretreatment biopsy specimens were pathologically evaluated. Expression statuses of CD8, forkhead box P3 (FOXP3), programmed cell death-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were assessed by immunohistochemistry. The relationships between immunological factors, including the tumor-infiltrating lymphocyte (TIL) grade and SUVmax or pathological complete response (pCR), were investigated. Results: CD8, FOXP3, PD-1, and PD-L1 were high in 15 (27.8%), 39 (72.2%), 18 (33.3%), and 26 (48.2%) patients, respectively. SUVmax was significantly correlated with tumor size, Ki-67 labeling index, and CD8/FOXP3 ratio. Multiple linear regression analysis indicated that tumor size and the CD8/FOXP3 ratio predicted SUVmax. Seventeen patients (31.5%) achieved a pCR; TILs, the CD8/FOXP3 ratio, PD-1, and PD-L1 were significantly correlated with pCR rate. Multivariate analysis indicated that the CD8/FOXP3 ratio was the only independent predictive factor for pCR. Conclusion: SUVmax could provide metabolic information regarding TIME for TNBC patients and might be beneficial for formulating a treatment strategy and predicting pCR after neoadjuvant chemotherapy.